Skip to main content
MedVellum
QuestionsVideosPricing

MedVellum

Fellowship exam preparation across every specialty: source-verified topics, questions in every format, and videos.

Product

  • Specialties
  • Questions
  • Videos
  • Exam tools
  • Pricing

Verification & policy

  • Verified register
  • Editorial policy
  • Privacy
  • Terms

Account

  • Sign in
  • Create account
  • Dashboard
  • Account & billing

© 2026 MedVellum. For education only — not a substitute for clinical judgement.

llms.txtPsychiatry LLM catalogSitemap

Psych TopicsAddiction psychiatry — substance-induced mood and anxiety disorders

Psych · Addiction psychiatry — substance-induced mood and anxiety disorders

Substance-induced mood and anxiety disorders

Also known as Substance-induced depressive disorder · Substance/medication-induced depressive disorder · Substance-induced bipolar disorder · Substance-induced anxiety disorder · Alcohol-induced depression · Stimulant crash dysphoria · Cannabis-induced anxiety · Medication-induced mood disorder · Secondary depression substance use · Induced vs independent depression

Exam-exhaustive fellowship reference on substance/medication-induced mood and anxiety disorders — DSM-5-TR and ICD-11 timing rules, alcohol stimulant and cannabis pathways, discriminators from independent mood/anxiety disorders, suicide risk windows, watchful waiting versus early antidepressant, dual-diagnosis management with named doses, and board discriminators. FRANZCP-primary, globally tagged.

high18 referencesUpdated 26 July 202614 min readVerification in progress

Practise this topic

  • 10 MCQs

Your progress

Saved on this device.

Practise this topic10 MCQs with explanations

Target exams

FRANZCPMRCPsychABPNMD-DNBNEET-SS

Red flags

  • Active suicidal intent or planning during stimulant crash, severe alcohol-related depression, or early withdrawal — same-day senior review, observation, and means restriction
  • Alcohol or benzodiazepine withdrawal risk with autonomic instability, seizures, or confusion — medical detox and thiamine before pure psychiatric labelling
  • New mania or mixed features with corticosteroids or other culprit medications on the drug chart — co-manage taper with the treating team
  • Depression or anxiety persisting substantially beyond the expected intoxication/withdrawal window after confirmed abstinence — reclassify toward independent disorder and treat fully
  • Chronic benzodiazepines layered onto dual alcohol/anxiety presentations — iatrogenic dependence risk
  • Do not dismiss all affective symptoms in heavy drinkers as trivial, and do not start lifelong polypharmacy on day one of intoxication without a timeline
On this page
Study tools

Your progress

Saved on this device.

Practise this topic10 MCQs with explanations

Target exams

FRANZCPMRCPsychABPNMD-DNBNEET-SS

Red flags

  • Active suicidal intent or planning during stimulant crash, severe alcohol-related depression, or early withdrawal — same-day senior review, observation, and means restriction
  • Alcohol or benzodiazepine withdrawal risk with autonomic instability, seizures, or confusion — medical detox and thiamine before pure psychiatric labelling
  • New mania or mixed features with corticosteroids or other culprit medications on the drug chart — co-manage taper with the treating team
  • Depression or anxiety persisting substantially beyond the expected intoxication/withdrawal window after confirmed abstinence — reclassify toward independent disorder and treat fully
  • Chronic benzodiazepines layered onto dual alcohol/anxiety presentations — iatrogenic dependence risk
  • Do not dismiss all affective symptoms in heavy drinkers as trivial, and do not start lifelong polypharmacy on day one of intoxication without a timeline
The one-line answer

Substance-induced mood and anxiety disorders are timeline diagnoses, not urine results — clinically significant depression, mania or anxiety that develops during or soon after intoxication, withdrawal, or a culprit medication, is not better explained by an independent mood or anxiety disorder, and is not only delirium. Treat medical and suicide risk first, prioritise substance cessation and dual care, allow a short supervised abstinence window for pure induced depression to remit, and start named antidepressant strategies earlier when independent illness, severity, or risk demands it.[1][2][5][8]

Meet the patient

A 47-year-old man is brought in by his wife. He has drunk heavily for three weeks after a job loss, and for the last week he has been unable to get out of bed, eating nothing, telling her he is worthless and the children are better off without him. His breath alcohol is positive tonight.[1][8]

The registrar writes depression, start SSRI. The examiner's question is the whole topic: is this an independent major depressive disorder that happens to drink, or an alcohol-induced depressive disorder — and what changes about tonight's plan depending on the answer?[1][4]

Psychiatry Fellowship Pro

Continue reading

You have read the opening of this topic. The complete unit — every section and its primary-source references — is part of the Psychiatry Fellowship fellowship library.

Sign in to continueSee pricing
References18ShowHide
  1. [1]Schuckit MA, Tipp JE, Bergman M, et al. Comparison of induced and independent major depressive disorders in 2,945 alcoholics Am J Psychiatry, 1997.PMID 9210745
  2. [2]Brown SA, Schuckit MA Changes in depression among abstinent alcoholics J Stud Alcohol, 1988.PMID 3216643
  3. [3]Schuckit MA, Smith TL, Kalmijn J Relationships among independent major depressions, alcohol use, and other substance use and related problems over 30 years in 397 families J Stud Alcohol Drugs, 2013.PMID 23384375
  4. [4]Grant BF, Stinson FS, Dawson DA, et al. Prevalence and co-occurrence of substance use disorders and independent mood and anxiety disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions Arch Gen Psychiatry, 2004.PMID 15289279
  5. [5]Nunes EV, Levin FR Treatment of depression in patients with alcohol or other drug dependence: a meta-analysis JAMA, 2004.PMID 15100209
  6. [6]Torrens M, Fonseca F, Mateu G, et al. Efficacy of antidepressants in substance use disorders with and without comorbid depression. A systematic review and meta-analysis Drug Alcohol Depend, 2005.PMID 15769553
  7. [7]Pettinati HM, Oslin DW, Kampman KM, et al. A double-blind, placebo-controlled trial combining sertraline and naltrexone for treating co-occurring depression and alcohol dependence Am J Psychiatry, 2010.PMID 20231324
  8. [8]McHugh RK, Weiss RD Alcohol Use Disorder and Depressive Disorders Alcohol Res, 2019.PMID 31649834
  9. [9]Boden JM, Fergusson DM Alcohol and depression Addiction, 2011.PMID 21382111
  10. [10]Kushner MG, Abrams K, Borchardt C The relationship between anxiety disorders and alcohol use disorders: a review of major perspectives and findings Clin Psychol Rev, 2000.PMID 10721495
  11. [11]Anker JJ, Kushner MG Co-Occurring Alcohol Use Disorder and Anxiety: Bridging Psychiatric, Psychological, and Neurobiological Perspectives Alcohol Res, 2019.PMID 31886106
  12. [12]Moore TH, Zammit S, Lingford-Hughes A, et al. Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review Lancet, 2007.PMID 17662880
  13. [13]McKetin R, Lubman DI, Baker AL, et al. Dose-related psychotic symptoms in chronic methamphetamine users: evidence from a prospective longitudinal study JAMA Psychiatry, 2013.PMID 23303471
  14. [14]Drake RE, Mercer-McFadden C, Mueser KT, et al. Review of integrated mental health and substance abuse treatment for patients with dual disorders Schizophr Bull, 1998.PMID 9853791
  15. [15]Hunt GE, Siegfried N, Morley K, et al. Psychosocial interventions for people with both severe mental illness and substance misuse Cochrane Database Syst Rev, 2019.PMID 31829430
  16. [16]Lingford-Hughes AR, Welch S, Peters L, et al. BAP updated guidelines: evidence-based guidelines for the pharmacological management of substance abuse, harmful use, addiction and comorbidity J Psychopharmacol, 2012.PMID 22628390
  17. [17]Malhi GS, Bell E, Bassett D, et al. The 2020 Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders Aust N Z J Psychiatry, 2021.PMID 33353391
  18. [18]Brown ES, Chandler PA Mood and cognitive changes during systemic corticosteroid therapy Prim Care Companion J Clin Psychiatry, 2001.PMID 15014624

Test yourself

Practise what you just read

  • 10 MCQs
Psychiatry Fellowship Pro

$29/ monthor $279 / year

The complete Psychiatry Fellowship library, every exam format, one subscription.

  • Complete library for one chosen specialty
  • Timed MCQ mock exams and spaced review
  • Clinical cases & cross-table vivas
See pricingSign in
PreviousStimulants and ADHD medicationsPsychopharmacology — stimulants and ADHD medicationsNextSubstance/medication-induced psychotic disorderGeneral adult psychiatry — substance/medication-induced psychosis